Neuro-Oncology · 2017 · 128 citations · 32 references
MedicineOncologyPharmacologyCancer PharmacologyMolecular OncologyTumor ProgressionBrain TumorsCancer ProgressionGlioblastomaOncogenic Signaling PathwaysRecurrent Brain TumorsTargeted Cancer TherapyEgfr InhibitionEpidermal Growth Factor Receptor InhibitionGlioblastoma Clinical TrialsGlioblastoma Drug TherapyGlioblastoma Molecular SubtypesGlioblastoma Targeted TherapyGlioblastoma TrialsRecurrence
BACKGROUND: We conducted a multicenter, 2-stage, open-label, phase II trial to assess the efficacy and safety of dacomitinib in adult patients with recurrent glioblastoma (GB) and epidermal growth factor receptor gene (EGFR) amplification with or without variant III (EGFRvIII) deletion. METHODS: Patients with first recurrence were enrolled in 2 cohorts. Cohort A included patients with EGFR gene amplification without EGFRvIII mutation. Cohort B included patients with EGFR gene amplification and EGFRvIII mutation. Dacomitinib was administered (45 mg/day) until disease progression/unacceptable adverse events (AEs). Primary endpoint was progression-free survival (PFS; RANO criteria) at 6 months (PFS6). RESULTS: Thirty patients in Cohort A and 19 in Cohort B were enrolled. Median age was 59 years (range 39-81), 65.3% were male, and Eastern Cooperative Oncology Group Performance Status 0/1/2 were 10.2%/65.3%/24.5%, respectively. PFS6 was 10.6% (Cohort A: 13.3%; Cohort B: 5.9%) with a median PFS of 2.7 months (Cohort A: 2.7 mo; Cohort B: 2.6 mo). Four patients were progression free at 6 months and 3 patients were so at 12 months. Median overall survival was 7.4 months (Cohort A: 7.8 mo; Cohort B: 6.7 mo). The best overall response included 1 complete response and 2 partial responses (4.1%). Stable disease was observed in 12 patients (24.5%: eight in Cohort A and four in Cohort B). Diarrhea and rash were the most common AEs; 20 (40.8%) patients experienced grade 3-4 drug-related AEs. CONCLUSIONS: Dacomitinib has a limited single-agent activity in recurrent GB with EGFR amplification. The detailed molecular characterization of the 4 patients with response in this trial can be useful to select patients who could benefit from dacomitinib.
32
Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Roger Stupp, Warren Mason, Martin J. van den Bent et al. · New England Journal of Medicine · 2005 · 21.6K citations · Full text
Analysis of the IDH1 codon 132 mutation in brain tumors
Jochen Meyer, Wolf Mueller, Andrey Korshunov et al. · Acta Neuropathologica · 2008 · 1K citations
Predicting lung cancer by detecting aberrant promoter methylation in sputum.
William A. Palmisano, Kevin K. Divine, Geno Saccomanno et al. · PubMed · 2000 · 817 citations